LT2515870T - Topinė akių peptidų kompozicija - Google Patents

Topinė akių peptidų kompozicija

Info

Publication number
LT2515870T
LT2515870T LTEP10810911.7T LT10810911T LT2515870T LT 2515870 T LT2515870 T LT 2515870T LT 10810911 T LT10810911 T LT 10810911T LT 2515870 T LT2515870 T LT 2515870T
Authority
LT
Lithuania
Prior art keywords
topical ophthalmic
peptide formulation
ophthalmic peptide
formulation
topical
Prior art date
Application number
LTEP10810911.7T
Other languages
English (en)
Inventor
Rafael Simo Canonge
Cristina Hernandez Pascual
Jimena Fernandez Carneado
Marc Gomez Caminals
Ribera Jordana I Lluch
Josep Farrera Sinfreu
Berta Ponsati Obiols
Original Assignee
Bcn Peptides, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2515870(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bcn Peptides, S.A. filed Critical Bcn Peptides, S.A.
Publication of LT2515870T publication Critical patent/LT2515870T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP10810911.7T 2009-12-22 2010-12-17 Topinė akių peptidų kompozicija LT2515870T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931242A ES2362604B1 (es) 2009-12-22 2009-12-22 Formulación tópica oftálmica de péptidos.
PCT/EP2010/007737 WO2011076368A2 (en) 2009-12-22 2010-12-17 Topical ophthalmic peptide formulation

Publications (1)

Publication Number Publication Date
LT2515870T true LT2515870T (lt) 2016-10-10

Family

ID=43928893

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10810911.7T LT2515870T (lt) 2009-12-22 2010-12-17 Topinė akių peptidų kompozicija

Country Status (34)

Country Link
US (1) US9216208B2 (lt)
EP (1) EP2515870B1 (lt)
JP (1) JP5920928B2 (lt)
KR (1) KR101657737B1 (lt)
CN (1) CN102753153B (lt)
AR (1) AR079683A1 (lt)
AU (1) AU2010335595B2 (lt)
BR (1) BR112012015386B8 (lt)
CA (1) CA2785104C (lt)
CL (1) CL2012001737A1 (lt)
CO (1) CO6592047A2 (lt)
CY (1) CY1117854T1 (lt)
DK (1) DK2515870T3 (lt)
ES (2) ES2362604B1 (lt)
HR (1) HRP20160954T1 (lt)
HU (1) HUE028193T2 (lt)
IL (1) IL220584A (lt)
LT (1) LT2515870T (lt)
MX (1) MX338323B (lt)
MY (1) MY178169A (lt)
NZ (1) NZ600627A (lt)
PH (1) PH12012501271A1 (lt)
PL (1) PL2515870T3 (lt)
PT (1) PT2515870T (lt)
RS (1) RS54953B1 (lt)
RU (1) RU2561585C2 (lt)
SG (1) SG181727A1 (lt)
SI (1) SI2515870T1 (lt)
SM (1) SMT201600277B (lt)
TW (1) TWI548416B (lt)
UA (1) UA108484C2 (lt)
UY (1) UY33153A (lt)
WO (1) WO2011076368A2 (lt)
ZA (1) ZA201204522B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6368722B2 (ja) 2013-03-01 2018-08-01 フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
CN110167516B (zh) 2017-01-31 2022-08-30 金伯利-克拉克环球有限公司 包含苯甲酸酯的抗细菌组合物及利用该组合物抑制细菌生长的方法
KR20200003923A (ko) * 2017-05-15 2020-01-10 썬 파마슈티컬 인더스트리스 리미티드 옥트레오티드 주사제
TW202133845A (zh) * 2019-11-21 2021-09-16 韓商三進製藥股份有限公司 用於預防或治療眼部疾病之眼用組合物
KR102741835B1 (ko) * 2022-03-11 2024-12-12 한국한의약진흥원 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물
CN120131956A (zh) * 2023-12-11 2025-06-13 中山大学中山眼科中心 生长激素抑制剂的用途、和含有生长激素抑制剂的药物组合物、制剂、及其装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
CN1244794A (zh) 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
CA2263042A1 (en) * 1999-02-25 2000-08-25 Robert W.A. Kuijpers Treatment of edema
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
AU2001283957A1 (en) 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
JP5165239B2 (ja) * 2003-07-15 2013-03-21 ピーアール ファーマシューティカルズ, インコーポレイテッド 制御放出処方物の調製のための方法
US20070082841A1 (en) * 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
CA2698666A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
ES2528409T3 (es) * 2007-10-24 2015-02-10 Camurus Ab Formulaciones de liberación controlada

Also Published As

Publication number Publication date
PL2515870T3 (pl) 2016-11-30
CL2012001737A1 (es) 2012-11-16
HUE028193T2 (en) 2016-12-28
IL220584A0 (en) 2012-08-30
UA108484C2 (en) 2015-05-12
KR101657737B1 (ko) 2016-09-19
CA2785104C (en) 2016-11-01
AU2010335595A1 (en) 2012-07-12
PT2515870T (pt) 2016-08-29
RS54953B1 (sr) 2016-11-30
ES2587828T3 (es) 2016-10-27
US9216208B2 (en) 2015-12-22
AU2010335595B2 (en) 2015-08-27
IL220584A (en) 2016-10-31
WO2011076368A2 (en) 2011-06-30
NZ600627A (en) 2014-08-29
CN102753153A (zh) 2012-10-24
KR20120120255A (ko) 2012-11-01
WO2011076368A3 (en) 2012-03-15
CY1117854T1 (el) 2017-05-17
MX338323B (es) 2016-04-12
SI2515870T1 (sl) 2016-09-30
CN102753153B (zh) 2015-11-25
CO6592047A2 (es) 2013-01-02
BR112012015386B1 (pt) 2021-02-23
JP2013515687A (ja) 2013-05-09
ES2362604B1 (es) 2012-06-28
DK2515870T3 (en) 2016-09-05
UY33153A (es) 2011-06-30
BR112012015386B8 (pt) 2021-05-25
HRP20160954T1 (hr) 2016-10-07
HK1178049A1 (zh) 2013-09-06
EP2515870B1 (en) 2016-05-25
CA2785104A1 (en) 2011-06-30
MX2012007282A (es) 2012-10-15
SMT201600277B (it) 2016-11-10
JP5920928B2 (ja) 2016-05-18
TW201141514A (en) 2011-12-01
SG181727A1 (en) 2012-07-30
AR079683A1 (es) 2012-02-15
BR112012015386A2 (pt) 2018-07-24
EP2515870A2 (en) 2012-10-31
TWI548416B (zh) 2016-09-11
MY178169A (en) 2020-10-06
US20130210728A1 (en) 2013-08-15
PH12012501271A1 (en) 2012-11-05
RU2561585C2 (ru) 2015-08-27
ZA201204522B (en) 2013-09-25
RU2012126028A (ru) 2014-01-27
ES2362604A1 (es) 2011-07-08

Similar Documents

Publication Publication Date Title
IL245328B (en) A pharmaceutical preparation containing carbatocin
ZA201304514B (en) Topical localized isoxazoline formulation
ZA201200719B (en) Pharmaceutical formulation
EP2659911A4 (en) AQUEOUS OPHTHALMIC COMPOSITION
EP2566487A4 (en) OPHTHALMIC COMPOSITION
PL2496596T3 (pl) Peptydy terapeutyczne
ZA201305591B (en) Fluorocarbon-linked peptide formulation
GB0921686D0 (en) Topical formulation
GB0912239D0 (en) Cosmetic formulation
EP2605786A4 (en) THERAPEUTIC PEPTIDES
IL220584A0 (en) Topical ophthalmic peptide formulation
GB0907003D0 (en) Formulation
WO2010114629A9 (en) Formulation
GB0908515D0 (en) Peptide
ZA201203722B (en) Peptide
GB0911213D0 (en) Formulation
GB0907410D0 (en) Formulation
GB201018773D0 (en) Topical pharmaceutical formulation
GB0918285D0 (en) Topical formulations
GB0918286D0 (en) Topical formulations
GB201013824D0 (en) Ophthalmic formulations
GB201007358D0 (en) Conjugated protein C
GB0906291D0 (en) Formulation
GB0902472D0 (en) Formulation
GB0914356D0 (en) Ophthalmic formulations